Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ZLAB Zai Lab Limited monthly Stock Chart
ZLAB [NASD]
Zai Lab Limited
Healthcare | Biotechnology | China
statements
Index- P/E- EPS (ttm)-2.05 Insider Own7.70% Shs Outstand73.99M Perf Week16.37%
Market Cap4.43B Forward P/E- EPS next Y-2.25 Insider Trans0.00% Shs Float68.37M Perf Month19.53%
Income-195.10M PEG- EPS next Q-0.85 Inst Own56.20% Short Float3.85% Perf Quarter47.04%
Sales13.00M P/S341.04 EPS this Y-14.60% Inst Trans0.48% Short Ratio5.01 Perf Half Y93.10%
Book/sh1.79 P/B33.47 EPS next Y20.50% ROA- Target Price70.00 Perf Year84.77%
Cash/sh3.73 P/C16.07 EPS next 5Y- ROE- 52W Range23.42 - 63.95 Perf YTD44.07%
Dividend- P/FCF- EPS past 5Y- ROI-67.50% 52W High-6.30% Beta-
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin71.10% 52W Low155.90% ATR4.20
Employees309 Current Ratio6.30 Sales Q/Q3488.20% Oper. Margin- RSI (14)62.06 Volatility6.90% 8.09%
OptionableYes Debt/Eq0.02 EPS Q/Q-103.40% Profit Margin- Rel Volume0.94 Prev Close55.11
ShortableYes LT Debt/Eq0.00 EarningsMar 19 BMO Payout- Avg Volume525.30K Price59.92
Recom1.60 SMA2018.80% SMA5011.28% SMA20045.43% Volume494,550 Change8.73%
Jul-12-19Initiated BofA/Merrill Buy
Jul-05-19Initiated Macquarie Outperform
Jan-29-19Initiated Credit Suisse Outperform
Nov-21-18Initiated Jefferies Buy
Jun-21-18Resumed Leerink Partners Outperform $43
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Oct-16-17Initiated Leerink Partners Outperform $42
Oct-16-17Initiated JP Morgan Neutral $32
Apr-08-20 06:00AM  Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) GlobeNewswire +7.30%
Mar-28-20 09:09PM  Hedge Funds Have Never Been This Bullish On Zai Lab Limited (ZLAB) Insider Monkey
Mar-19-20 12:21PM  Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates PR Newswire
11:30AM  Is Zai Lab Limited Unsponsored (ZLAB) Outperforming Other Medical Stocks This Year? Zacks
07:30AM  Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates GlobeNewswire
06:30AM  Zai Lab Ltd. to Host Earnings Call ACCESSWIRE
Mar-16-20 07:30AM  Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA GlobeNewswire -13.82%
Mar-05-20 07:30AM  Zai Lab to Announce Financial Results for the Full Year Ended December 31, 2019 and Corporate Updates on March 19, 2020 GlobeNewswire
Feb-11-20 07:30AM  Zai Lab Announces Upcoming Participation at February Conferences GlobeNewswire
07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
06:47AM  Will Zai Lab Continue to Surge Higher? Zacks
Feb-10-20 07:30AM  Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA GlobeNewswire +5.01%
Feb-04-20 07:30AM  Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies GlobeNewswire
Jan-27-20 04:30PM  Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option GlobeNewswire
Jan-22-20 09:43PM  Zai Lab Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire -7.02%
Jan-21-20 04:34PM  Zai Lab Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Jan-14-20 07:30AM  Zai Lab Appoints Lonnie Moulder to Board of Directors GlobeNewswire +10.62%
Jan-09-20 07:30AM  Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer GlobeNewswire
Dec-30-19 06:55AM  How Does Zai Lab Limited (NASDAQ:ZLAB) Affect Your Portfolio Volatility? Simply Wall St.
Dec-27-19 08:46AM  Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 27, 2019: NKE, AXE, PT, FLXN, ZLAB Benzinga +5.28%
07:41AM  Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer GlobeNewswire
Dec-23-19 07:30AM  Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-19 07:30AM  Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board GlobeNewswire -6.04%
Dec-08-19 06:26PM  Hedge Funds Have Never Been This Bullish On Zai Lab Limited (ZLAB) Insider Monkey
Oct-30-19 07:30AM  Zai Lab Announces Upcoming Presentations at November Conferences GlobeNewswire
Oct-27-19 04:16PM  Heres What Hedge Funds Think About Zai Lab Limited (ZLAB) Insider Monkey
Oct-25-19 08:30AM  Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer GlobeNewswire +5.22%
Oct-24-19 08:30AM  Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer GlobeNewswire
Oct-04-19 07:30AM  Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference GlobeNewswire
Sep-29-19 02:15PM  Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer GlobeNewswire
Sep-11-19 12:22PM  Should Zai Lab (NASDAQ:ZLAB) Be Disappointed With Their 93% Profit? Simply Wall St.
Sep-03-19 06:01PM  Zai Lab Limited (ZLAB) Q2 2019 Earnings Call Transcript Motley Fool
07:32AM  Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019 GlobeNewswire
06:30AM  Zai Lab Ltd. to Host Earnings Call ACCESSWIRE
Aug-27-19 07:30AM  Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients GlobeNewswire -7.42%
Aug-26-19 07:30AM  Zai Lab Announces Upcoming Presentations at September Conferences GlobeNewswire
Aug-20-19 07:30AM  Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019 GlobeNewswire
Aug-12-19 07:30AM  China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China GlobeNewswire
07:30AM  China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China Business Wire
Jul-05-19 04:01PM  Here is What Hedge Funds Think About Zai Lab Limited (ZLAB) Insider Monkey
Jul-02-19 07:42AM  Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China MarketWatch
07:30AM  Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China GlobeNewswire
07:30AM  Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China Business Wire
Jun-24-19 05:00AM  China biotech groups spend billions on overseas drug candidates Financial Times
Jun-12-19 09:23AM  Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer GlobeNewswire
Jun-11-19 08:09AM  Do Insiders Own Lots Of Shares In Zai Lab Limited (NASDAQ:ZLAB)? Simply Wall St.
07:00AM  Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China GlobeNewswire
07:00AM  Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China Business Wire
Jun-03-19 07:30AM  Zai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer GlobeNewswire
May-29-19 07:30AM  Zai Lab Announces Presentations at June Conferences GlobeNewswire
May-16-19 07:30AM  Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections GlobeNewswire
May-09-19 07:30AM  Zai Lab Announces Participation at Upcoming May Conferences GlobeNewswire
May-03-19 08:29PM  Heres What Hedge Funds Think About Zai Lab Limited (ZLAB) Insider Monkey
May-02-19 07:18PM  Zai Lab Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire
May-01-19 05:00PM  3 Top Chinese Stocks to Watch in May Motley Fool
04:05PM  Zai Lab Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Apr-17-19 07:30AM  Zai Lab to Host Analyst & Investor Day on April 30, 2019 GlobeNewswire
Mar-30-19 10:06AM  Did Zai Lab's (NASDAQ:ZLAB) Share Price Deserve to Gain 38%? Simply Wall St.
Mar-12-19 07:30AM  Zai Lab Announces Presentations at March Conferences GlobeNewswire
Mar-07-19 07:30AM  Zai Lab Announces Financial Results and Corporate Update for Full Year 2018 GlobeNewswire
Feb-27-19 12:06AM  Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-21-19 07:30AM  Zai Lab to Announce Full Year 2018 Financial Results GlobeNewswire
Feb-20-19 07:30AM  Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-07-19 08:08AM  The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut Benzinga
Feb-06-19 06:16PM  MacroGenics stock spikes from positive results of cancer drug trial American City Business Journals +14.40%
Feb-01-19 09:06AM  Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye Zacks
07:30AM  Zai Lab Announces the Appointment of Immuno-Oncology Pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board GlobeNewswire
Jan-31-19 08:43AM  5 Stocks With Recent Price Strength to Enhance Your Return Zacks
Jan-28-19 07:30AM  Priority Review Granted to Zai Labs NDA Application for ZEJULA (Niraparib) in China GlobeNewswire
Jan-23-19 08:19AM  Moving Average Crossover Alert: Zai Lab Limited Zacks
06:08AM  Will Zai Lab Continue to Surge Higher? Zacks
Jan-15-19 05:08PM  Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line American City Business Journals +7.25%
Jan-09-19 07:30AM  Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China GlobeNewswire
Dec-28-18 07:30AM  Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme GlobeNewswire
Dec-19-18 07:30AM  Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-18 10:05AM  Zai Lab Limited (ZLAB): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-12-18 07:30AM  Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA GlobeNewswire +5.27%
Dec-03-18 09:00AM  George Soros Bought These 2 Healthcare Stocks in the Third Quarter Motley Fool
Nov-29-18 07:30AM  MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT Molecule in Greater China GlobeNewswire
Nov-14-18 07:30AM  Zai Lab and Novocure Awarded Deal of the Year GlobeNewswire
Nov-07-18 07:30AM  Zai Lab Limited Announces Presentations at November Conferences GlobeNewswire +6.27%
Oct-22-18 07:30AM  Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong GlobeNewswire
Oct-01-18 08:00AM  Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers Business Wire
Sep-27-18 07:30AM  Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence GlobeNewswire
Sep-26-18 07:30AM  Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
07:30AM  Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
Sep-25-18 07:30AM  Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable GlobeNewswire
Sep-12-18 04:20PM  Zai Lab to Host Conference Call to Discuss its License and Collaboration Agreement with Novocure for Tumor Treating Fields in Greater China GlobeNewswire
07:30AM  Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China Business Wire
Sep-06-18 01:04PM  Here's Why Zai Lab Limited Dropped Today Motley Fool -10.98%
Sep-05-18 08:59PM  Zai Lab Announces Pricing of Public Offering of American Depositary Shares GlobeNewswire
Sep-02-18 07:30PM  Zai Lab Announces Proposed Public Offering of American Depositary Shares GlobeNewswire
Aug-30-18 07:30AM  Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018 GlobeNewswire
Aug-29-18 08:51AM  Zai Lab (ZLAB) in Focus: Stock Moves 6.2% Higher Zacks -10.34%
Aug-28-18 07:30AM  Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China GlobeNewswire +6.16%
Aug-27-18 10:52AM  Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails Zacks
Aug-24-18 08:00AM  Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis GlobeNewswire
Aug-22-18 08:00AM  Zai Lab Announces Presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the IASLC 19th World Conference on Lung Cancer (WCLC) GlobeNewswire
12:45AM  U.S.-listed Chinese biotech Zai Lab plans Hong Kong float -sources Reuters
Aug-20-18 07:30AM  Zai Labs ZL-2306 (niraparib) Completes Pharmacokinetics (PK) Study in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients GlobeNewswire
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, infectious, and autoimmune diseases in China and internationally. The company's lead drug candidate is ZL-2306, an oral small molecule PARP 1/2 inhibitor for treatment of multiple solid tumor, including ovarian and other types of cancer. Its products in Phase III clinical trial comprise Niraparib, a small molecule PARP 1/2 inhibitor for the treatment of multiple solid tumor types; Optune, a cancer therapy; Margetuximab, an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Brivanib, a small molecule dual target tyrosine kinase inhibitor for the treatment of hepatocellular carcinoma; and Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, community-acquired bacterial pneumonia, and urinary tract infections. The company's clinical stage products also include MGD013, a bispecific DART molecule that is in Phase I clinical trial for the treatment of various solid tumors and hematological malignancies; and ETX2514, a novel beta-lactamase inhibitor that has completed Phase II cUTI trial for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Bristol-Myers Squibb Company; Entasis Therapeutics Holdings, Inc.; Sanofi; MacroGenics Inc.; and NovoCure Limited. The company was founded in 2013 and is headquartered in Shanghai, China.
open in yahoo | open in reuters | open in google